ArticleJournal of medicinal chemistry2026
Chemical Stabilization and Transformation of Schiff Base Scaffold: A Path toward Superior Platinum-Based Anti-Cancer Stem Cell Drugs.
Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The clinical application of platinum-based anticancer agents is limited by poor aqueous stability, low solubility, and dose-limiting toxicities. Here, we report two Pt(II) complexes based on a Schiff base ligand and its reduced imine derivative, designed to overcome these limitations. We show that ligand stabilization through imine reduction markedly improves solution stability, which emerges as an important contributor to interaction, cellular responses, and antiproliferative activity. ICP-MS analysis demonstrated efficient intracellular platinum accumulation with preferential nuclear localization. The lead compound also displayed potent activity against gastric cancer stem-like cells by impairing self-renewal and pluripotency. Transcriptomic and functional analyses associated this effect with suppression of stemness and epithelial-to-mesenchymal transition-related transcriptional programs, reduced OCT3/4 expression, and activation of DNA damage, apoptosis, and oxidative stress pathways. These findings identify a promising Pt(II) scaffold for targeting cancer stem cell-associated phenotypes and establish ligand stabilization as an effective strategy for developing next-generation platinum anticancer agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.